Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to ...
SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM). This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not ...
Exposure to asbestos is the major risk factor for malignant mesothelioma, a type of aggressive cancer that mostly affects the pleura - the tissue that lines the lungs - and the peritoneum - the tissue ...
Exposure to asbestos is the major risk factor for malignant mesothelioma, a type of aggressive cancer that mostly affects the pleura - the tissue that lines the lungs - and the peritoneum - the tissue ...
Data presented by Dr. Dean Fennell in an oral presentation at the IASLC 2023 World Conference on Lung Cancer in Singapore CAMBRIDGE, Mass.--(BUSINESS WIRE)--RS Oncology, a clinical stage biotechnology ...
While many patients with mesothelioma — a type of rare cancer that most commonly occurs in the membrane between the lungs and the chest wall — may not be eligible to undergo surgery, drug advancements ...
Introduction: Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is increasing in frequency worldwide. Treatment options are limited, and response to chemotherapy is poor. The ...
Scientists at Ruhr-Universität Bochum have established a process for identifying biomarkers for the diagnosis of different types of cancer. With the aid of a specific type of infrared (IR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback